

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Critical Care Medicine

ESPS manuscript NO: 19900

Title: Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?

Reviewer's code: 00502797

Reviewer's country: Greece

Science editor: Yue-Li Tian

Date sent for review: 2015-05-26 19:43

Date reviewed: 2015-06-08 05:28

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is an Editorial article, where the authors follow all the rules of writing a scientific article. They discuss an interesting subject, while there is lack of data in the world literature. Finally, I enjoy reading this article and therefore I think that it could be published into the journal

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Critical Care Medicine

ESPS manuscript NO: 19900

Title: Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?

Reviewer's code: 00502750

Reviewer's country: Australia

Science editor: Yue-Li Tian

Date sent for review: 2015-05-26 19:43

Date reviewed: 2015-06-30 18:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

A timely manuscript for the developing world

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Critical Care Medicine

ESPS manuscript NO: 19900

Title: Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?

Reviewer's code: 00502781

Reviewer's country: Finland

Science editor: Yue-Li Tian

Date sent for review: 2015-05-26 19:43

Date reviewed: 2015-06-16 18:16

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Pulmonary hypertension (PH) encompasses a very broad group of cardiovascular diseases including pulmonary arterial hypertension (PAH), PH associated with left-sided heart disease (LHD), chronic lung diseases, and chronic thromboembolism. In their Editorial, Nakos and Papathanasiou highlight the need of novel therapies targeting PH associated with LHD and lung diseases. I have some concerns that require attention. Major comments - The authors should give references to the statements in Chapter 2. - The authors should specify the role of prostacyclin and its stable analogues in the treatment of PAH/PH, i.e. explain the term epoprostanoids. They could mention that bosentan is a nonselective endothelin-1 receptor antagonist and sildenafil is a phosphodiesterase-5 inhibitor. - The role of soluble guanylate cyclase stimulators, especially Riociguat in the treatment of PH and PAH should be addressed, and an appropriate reference for current clinical management of PAH (for example, Humbert M et al. Circulation 2014;130:2189-2208) could be given. Minor comments - The authors should explain all abbreviations and perform proof-reading more carefully. - The content in the penultimate chapter might be combined with



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

previous chapters.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Critical Care Medicine

ESPS manuscript NO: 19900

Title: Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?

Reviewer's code: 00502828

Reviewer's country: Japan

Science editor: Yue-Li Tian

Date sent for review: 2015-05-26 19:43

Date reviewed: 2015-05-29 02:14

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Thank you for a nice editorial article. I have two major comments on the manuscript. #1. Definitions of PH groups II, III and IV are not shown in the manuscript. Please create the table which defines PH groups I, II, III and IV. #2. Many abbreviations are used in the article. I found some difficulties in distinguishing COPD from DPLD. Please summarize the abbreviations and definitions.